证券代码：688566 证券简称：吉贝尔 公告编号：2024-027 江苏吉贝尔药业股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第七次会 议（以下简称"会议"）经公司全体监事同意豁免会议通知时间要求，于 2024 年 5 月 20 日在公司会议室召开。会议应参加表决监事 3 名，实际参加表决监事 3 名。本次会议符合《中华人民共和国公司法》（以下简称"《公司法》"）及《江 苏吉贝尔药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，会议 合法有效。 表决情况：3 票同意、0 票反对和 0 票弃权。 二、监事会会议审议情况 会议由监事会主席王正先生主持，经认真审议，形成以下决议： （一）逐项审议通过《关于公司与特定对象签署附生效条件的股份认购协 议的补充协议的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理办法》及《上 海证券交易所上市公司证券发行与承销业务实施细则》等相关 ...

证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2023 年年度股东大会 会议资料 二〇二四年五月 江苏吉贝尔药业股份有限公司 2023 年年度股东大会会议资料 江苏吉贝尔药业股份有限公司 2023 年年度股东大会会议须知 为了维护公司全体股东的合法权益，确保股东大会的正常秩序和议事效 率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东大会规则》以及《江苏吉贝尔药业股份有限公司章程》等 相关规定，江苏吉贝尔药业股份有限公司（以下简称"公司"）特制定本次股 东大会会议须知： 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工 作； 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务 请出席大会的股东或其代理人及其他出席、列席人员准时到达会场签到确认参 会资格。会议开始后，会议登记应当终止，由会议主持人宣布现场出席会议的 股东和代理人人数及所持有的表决权数量； 三、会议按照会议通知上所列顺序审议、表决议案； 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会 召开前一天向大会会务组进行登记。大会主持人根据会务 ...

Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes no cash dividends, no bonus shares, and no capital reserve transfers [2][3] - The board has proposed to authorize the board to formulate a specific plan for the 2024 interim dividend, which will be reviewed at the 2023 annual shareholders' meeting [4] Group 2: Product Development and Clinical Trials - The company has developed a new diabetes drug, JJH202301, which has shown promising results in preliminary pharmacokinetic tests, significantly extending the drug's half-life and reducing metabolite production [2] - The anti-cancer drug JJH201601 has received approval for clinical trials in advanced solid tumors and is currently in Phase I clinical research [3][5] - The company has patented multiple formulations of the drug Likujun, enhancing its market protection and ensuring product quality [3] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is the leading product in this category [5] - Sales data indicates uneven development across different regions, suggesting a large untapped market nationally [5] - The company is actively promoting Likujun in oncology and other key areas, contributing to sustained growth in operating performance [4]

Investment Rating - The investment rating for the company is "Buy" with a 6-month outlook [1][17]. Core Insights - The company is actively expanding its molecular block business, enhancing front-end and back-end collaboration. The unique product, Nigulol Tablets, has strong scarcity and the sales team is gradually improving [1]. - In 2023, the company achieved a revenue of 861 million yuan, a year-on-year increase of 31.49%, and a net profit of 219 million yuan, up 41.65% year-on-year. The gross margin was 88.95% and the net margin was 25.41% [9]. - The company expects revenue growth to continue, projecting revenues of 1.07 billion yuan in 2024, 1.31 billion yuan in 2025, and 1.59 billion yuan in 2026, with corresponding net profits of 281 million yuan, 351 million yuan, and 429 million yuan respectively [17][30]. Financial Performance Summary - The company's revenue growth rates are projected at 23.80% for 2024, 22.72% for 2025, and 21.74% for 2026 [30]. - The gross margin is expected to remain stable around 88% over the forecast period [30]. - The earnings per share (EPS) are projected to be 1.49 yuan in 2024, 1.86 yuan in 2025, and 2.27 yuan in 2026 [30]. Product Performance - Nigulol Tablets generated revenue of 90 million yuan in 2023, with a year-on-year growth of 61.04% and a gross margin of 94%. The sales volume reached 32.55 million tablets, up 60.89% year-on-year [22]. - The product is recognized as a recommended domestic innovative drug for treating hypertension combined with rapid heart rate, with a significant patient population [22]. - The company’s other product, Likujun Tablets, achieved revenue of 653 million yuan in 2023, a growth of 29.91%, with a gross margin of 92.6% [28]. Innovation Pipeline - The company has advanced its innovative drug pipeline, with JJH201501 entering Phase III clinical trials and other drugs progressing through various stages of development [28]. - The global antidepressant market is expanding, with significant potential for the company's new drug developments in this area [28]. Market Position - The company is positioned well within the pharmaceutical industry, focusing on innovative drug development and expanding its market share through strategic product offerings and collaborations [1][28].

Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes not paying cash dividends or issuing bonus shares [1][2][3] - The board has proposed to authorize the formulation of a mid-year dividend plan for 2024, which will be reviewed at the 2023 annual shareholders' meeting [4] - The company emphasizes investor returns and aims to balance long-term development with reasonable returns to investors [4] Group 2: Product Development and Clinical Trials - The company has introduced a new diabetes medication, JJH202301, which has shown promising results in preliminary pharmacokinetic studies, indicating a significant extension of the drug's half-life and reduced metabolite production [2][3] - The anti-cancer drug JJH201601 has received approval for clinical trials and is currently in Phase I studies, with multiple dosage groups already enrolled [3][5] - The company has patented multiple formulations of its existing drug, Likujun, to enhance product quality and clinical efficacy, thereby reducing the risk of imitation [3][5] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is positioned as a leading product in this category [5][6] - Sales data indicates uneven development across different regions, suggesting a considerable untapped market nationally [5] - The application of Likujun in oncology has been recognized in clinical guidelines, further enhancing its market prospects [5][6]

根据申报材料：（1）本次募投新药研发项目与前次募投中均包括 JJH201501Ⅲ期临 床研究。前次募投项目中"国家一类抗抑郁新药（JJH201501）、国家一类抗肿瘤新药 （JJH201601）研发与试验项目"的内容包括对沃替西汀衍生物（JJH201501）开展Ⅰ至 Ⅲ期临床试验；本次募投项目 JJH201501 研发项目拟投向 JJH201501 的Ⅲ期临床研究 10,000.00 万元；2）报告期各期末，发行人的资产负债率分别为 9.78%、11.57%、13.76%、 12.98%。 请发行人：（1）结合招股说明书披露的前次募投项目中 JJH201601、JJH201501 的 项目投资情况、研发进展及募集资金使用情况，说明 JJH201501 研发项目（Ⅲ期临床研 究）本次募投项目与前次募投项目投资金额存在差异的合理性，本次募集说明书与招股 说明书等申报文件信息披露是否存在不一致；（2）结合本次募投项目中 JJH201501 研发 项目（Ⅲ期临床研究）与前次募投相关项目的区别与联系，说明本次募集资金继续投向 前次募投项目的必要性；如不能充分说明必要性，发行人应按照再融资监管要求合理确 定本次募投项目融 ...

关于江苏吉贝尔药业股份有限公司 以简易程序向特定对象发行股票 审核中心意见落实函的回复 保荐机构（主承销商） | | | （成都市青羊区东城根上街95号） 二〇二四年四月 上海证券交易所： 国金证券股份有限公司（以下简称"保荐机构""国金证券"）作为江苏吉贝 尔药业股份有限公司（以下简称"吉贝尔""公司"或"发行人"）以简易程序向 特定对象发行股票的保荐机构（主承销商），会同相关各方，对贵所落实意见中 所提及的相关问题进行了认真核查，并出具本回复，请贵所予以审核。（如未经 说明，本回复中的简称与募集说明书中的简称具有相同含义。） 问题 1、关于本次募投项目 根据申报材料：（1）本次募投新药研发项目与前次募投中均包括 JJH201501 Ⅲ期临床研究。前次募投项目中"国家一类抗抑郁新药（JJH201501）、国家一 类抗肿瘤新药（JJH201601）研发与试验项目"的内容包括对沃替西汀衍生物 （JJH201501）开展Ⅰ至Ⅲ期临床试验；本次募投项目 JJH201501 研发项目拟 投向 JJH201501 的Ⅲ期临床研究 10,000.00 万元；2）报告期各期末，发行人的 资产负债率分别为 9.78%、11. ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-024 1 江苏吉贝尔药业股份有限公司 关于以简易程序向特定对象发行股票申请获得上海 证券交易所审核通过的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏吉贝尔药业股份有限公司（以下简称"公司"）收到上海证券交易所就 公司 2023 年度以简易程序向特定对象发行 A 股股票事项申请的审核意见： 根据《上海证券交易所上市公司证券发行上市审核规则》，江苏吉贝尔药业 股份有限公司以简易程序向特定对象发行股票符合发行条件、上市条件和信息披 露要求。 公司本次以简易程序向特定对象发行 A 股股票事项尚需获得中国证券监督 管理委员会（以下简称"中国证监会"）作出同意注册的决定。最终能否获得中 国证监会同意注册的决定及其时间尚存在不确定性。公司将根据该事项的进展情 况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 江苏吉贝尔药业股份有限公司董事会 2024 年 5 月 10 日 ...

| 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度， | 保荐机构已建立健全并有效执行了 | | | 并针对具体的持续督导工作制定相应的工 | 持续督导制度，并制定了相应的工 | | | 作计划 | 作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与吉贝尔签订《保荐协 | | | 开始前，与上市公司或相关当事人签署持续 | 议》，该协议明确了双方在持续督导期 | | | 督导协议，明确双方在持续督导期间的权利 | 间的权利和义务，并报上海证券交 | | | 义务，并报上海证券交易所备案 | 易所备案 | | 3 | | 保荐机构通过日常沟通、定期或不 | | | 通过日常沟通、定期回访、现场检查、尽职 | 定期回访、现场检查等方式，了解 | | | 调查等方式开展持续督导工作 | 吉贝尔业务情况，对吉贝尔开展了 | | | | 持续督导工作 | | | 持续督导期间，按照有关规定对上市公司违 | 吉贝尔在本持续督导期间未发生按 | | | 法违规事项公开发表声明的，于披露前向上 | | | 4 | ...